{"disease":{"id":"cholera","name":"Cholera","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":5,"pipeline_drug_count":0,"trial_count":3},"drugs":{"marketed":[{"drug_id":"doxycycline","indication_name":"Cholera","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"fusidic-acid","indication_name":"Cholera","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"doxycyclin","indication_name":"Cholera","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Doxycyclin","company_name":"Bulovka Hospital","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"minocycline","indication_name":"Cholera","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Minocycline Hydrochloride","generic_name":"MINOCYCLINE","company_name":"Rempex","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Drug","quality_score":75,"revenue":null,"mechanism":"MINOCYCLINE works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"doxycycline","indication_name":"Cholera","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vibramycin","generic_name":"doxycycline","company_name":"Generic (originally Pfizer)","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase, Stromelysin-1, Collagenase 3","drug_class":"Tetracycline antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"minocyclin","indication_name":"Cholera","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Minocyclin","company_name":"University of Southern California","drug_phase":"marketed","molecular_target":"30S ribosomal protein S4, 30S ribosomal protein S9, Tetracycline resistance protein, class B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02027207","title":"Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":204438,"lead_sponsor_name":"International Centre for Diarrhoeal Disease Research, Bangladesh","has_results":false},{"nct_id":"NCT02727855","title":"Cholera Vaccine Investment Strategy in Bangladesh","phase":"","overall_status":"COMPLETED","enrollment_count":75170,"lead_sponsor_name":"International Centre for Diarrhoeal Disease Research, Bangladesh","has_results":false},{"nct_id":"NCT07358910","title":"Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Institut Pasteur du Cambodge","has_results":false},{"nct_id":"NCT05829772","title":"Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence","phase":"","overall_status":"COMPLETED","enrollment_count":7000,"lead_sponsor_name":"Epicentre","has_results":false},{"nct_id":"NCT04853186","title":"Impact Study of Cholera Vaccination in Endemic Areas - Clinical Surveillance","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Epicentre","has_results":false},{"nct_id":"NCT06003816","title":"Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)","phase":"NA","overall_status":"RECRUITING","enrollment_count":3140,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT05166850","title":"Preventative Intervention for Cholera for 7 Days","phase":"NA","overall_status":"RECRUITING","enrollment_count":2900,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT04008134","title":"Cholera-Hospital-Based-Intervention-for-7-days","phase":"NA","overall_status":"COMPLETED","enrollment_count":2626,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT04760236","title":"Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2530,"lead_sponsor_name":"International Vaccine Institute","has_results":false},{"nct_id":"NCT05507229","title":"A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131).","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":1800,"lead_sponsor_name":"Bharat Biotech International Limited","has_results":false},{"nct_id":"NCT06498817","title":"Testing a Scalable Model of the Cholera Hospital-Based Intervention for 7 Days (CHoBI7)","phase":"NA","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT06455852","title":"Vaccine- and Infection-derived Correlates of Protection for Cholera","phase":"NA","overall_status":"RECRUITING","enrollment_count":1221,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT04326478","title":"Single Dose Azithromycin to Prevent Cholera in Children","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":920,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03220737","title":"VAXCHORA Pediatric Study to Assess Safety and Immunogenicity","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":550,"lead_sponsor_name":"Bavarian Nordic","has_results":true},{"nct_id":"NCT05453253","title":"Immune Response to a Delayed Second Dose of Oral Cholera Vaccine","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":456,"lead_sponsor_name":"Epicentre","has_results":false},{"nct_id":"NCT00401934","title":"Immunity to Human Cholera in Bangladesh","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05814042","title":"Next Generation ORS: Comparing ORS With Calcium vs Standard ORS in Reducing Severity of Acute Watery Diarrhea","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":396,"lead_sponsor_name":"University of Florida","has_results":true},{"nct_id":"NCT04816552","title":"Water, Sanitation, and Hygiene Mobile Health Messages as an Innovative Tool to Facilitate Behavior Change","phase":"NA","overall_status":"COMPLETED","enrollment_count":284,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":true},{"nct_id":"NCT03705585","title":"CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false},{"nct_id":"NCT03719066","title":"Extended Dose Intervals With Oral Cholera Vaccine in Cameroon","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":181,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT05559983","title":"Dose Escalation Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"International Vaccine Institute","has_results":false},{"nct_id":"NCT06193408","title":"Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Hunazine Biotech S.L.","has_results":true},{"nct_id":"NCT03373669","title":"Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT06929312","title":"Simulation Based Training In Medical Students","phase":"NA","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"CMH Lahore Medical College and Institute of Dentistry","has_results":false},{"nct_id":"NCT03998449","title":"Immunogenicity of Cholera Vaccine in Children With IBD","phase":"NA","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Medical University of Warsaw","has_results":false},{"nct_id":"NCT06104345","title":"Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Helsinki University Central Hospital","has_results":false},{"nct_id":"NCT03237663","title":"Safety of An Oral O1 / O139 Cholera Vaccine (Enteric Capsules)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Jiangsu Province Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT05657782","title":"First in Human Phase 1 Ascending Dose Study of PanChol in Healthy Volunteers","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":53,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT04150250","title":"Cholera Anti-Secretory Treatment Trial","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"PATH","has_results":true},{"nct_id":"NCT03251495","title":"Immunologic Responses to a Live Attenuated Oral Cholera Vaccine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT07107516","title":"Phase 1b Ascending Dose Study of PanChol in Healthy Volunteers","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":32,"lead_sponsor_name":"Centre for Infectious Disease Research in Zambia","has_results":false},{"nct_id":"NCT03724357","title":"Blood Donor CVD 9000","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":true}],"total":32},"guidelines":[],"source":"Drug Landscape verified database"}